Davita Battle Creek Dialysis is a medicare approved dialysis facility center in Battle Creek, Michigan and it has 20 dialysis stations. It is located in Calhoun county at 220 Goodale Ave E Ste B, Battle Creek, MI, 49037. You can reach out to the office of Davita Battle Creek Dialysis at (269) 968-8401. This dialysis clinic is managed and/or owned by Davita. Davita Battle Creek Dialysis has the following ownership type - Profit. It was first certified by medicare in November, 1977. The medicare id for this facility is 232617 and it accepts patients under medicare ESRD program.
| Name | Davita Battle Creek Dialysis |
|---|---|
| Location | 220 Goodale Ave E Ste B, Battle Creek, Michigan |
| No. of Dialysis Stations | 20 |
| Medicare ID | 232617 |
| Managed By | Davita |
| Ownership Type | Profit |
| Late Shifts | No |
| 220 Goodale Ave E Ste B, Battle Creek, Michigan, 49037 | |
| (269) 968-8401 | |
News Archive
In a major step toward commercialization of a promising therapeutic treatment, Oak Ridge National Laboratory contractor UT-Battelle announced at a signing ceremony here today that it has exclusively licensed patents on inventions based on the Nell-1 gene to NellOne Therapeutics, Inc. (NellOne), a company spun out of research performed at the Department of Energy laboratory.
DaVita Clinical Research, a specialty contract research organization with services spanning a broad spectrum of drug and device development, announced today its Biospecimen Research Grant Program (BioReG), a grant program to award clinical-trial-quality biospecimens and annotated de-identified data to academic medical centers involved in kidney research.
Magellan Biosciences, a global manufacturer of products designed to make diagnostic testing easier, more cost-effective, and less labor intensive, announced that it has sold its microbiology business, TREK Diagnostic Systems, to Thermo Fisher Scientific.
NexBio, Inc. announced today the initiation of a trial of DAS181 (Fludase®) in patients with the respiratory conditions asthma and bronchiectasis, being conducted by researchers with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH). This trial will examine the effects of DAS181 in subjects with well-controlled or stable pulmonary disease.
Concentric Medical, Inc., the global leader in acute ischemic stroke intervention, today announced that its Trevo System for acute ischemic stroke has received regulatory approval in both Europe (CE Mark) and Canada.
› Verified 5 days ago
| NPI Number | 1710948203 |
| Organization Name | Battle Creek Dialysis |
| Doing Business As | Renal Treatment Centers Illinois Inc |
| Address | 220 E Goodale Ave Battle Creek, Michigan, 49037 |
| Phone Number | (269) 968-8401 |
News Archive
In a major step toward commercialization of a promising therapeutic treatment, Oak Ridge National Laboratory contractor UT-Battelle announced at a signing ceremony here today that it has exclusively licensed patents on inventions based on the Nell-1 gene to NellOne Therapeutics, Inc. (NellOne), a company spun out of research performed at the Department of Energy laboratory.
DaVita Clinical Research, a specialty contract research organization with services spanning a broad spectrum of drug and device development, announced today its Biospecimen Research Grant Program (BioReG), a grant program to award clinical-trial-quality biospecimens and annotated de-identified data to academic medical centers involved in kidney research.
Magellan Biosciences, a global manufacturer of products designed to make diagnostic testing easier, more cost-effective, and less labor intensive, announced that it has sold its microbiology business, TREK Diagnostic Systems, to Thermo Fisher Scientific.
NexBio, Inc. announced today the initiation of a trial of DAS181 (Fludase®) in patients with the respiratory conditions asthma and bronchiectasis, being conducted by researchers with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH). This trial will examine the effects of DAS181 in subjects with well-controlled or stable pulmonary disease.
Concentric Medical, Inc., the global leader in acute ischemic stroke intervention, today announced that its Trevo System for acute ischemic stroke has received regulatory approval in both Europe (CE Mark) and Canada.
› Verified 5 days ago
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Patients who reported that nephrologists always communicated and cared for them. | 82% | 67% |
| Patients who reported that nephrologists usually communicated and cared for them. | 9% | 15% |
| Patients who reported that nephrologists sometimes or never communicated and cared for them. | 9% | 18% |
| Patients who gave their nephrologists a rating of 9 or 10 on a scale of 0 (worst possible) to 10 (best possible). | 81% | 60% |
| Patients who gave their nephrologists a rating of 7 or 8 on a scale of 0 (worst possible) to 10 (best possible). | 13% | 26% |
| Patients who gave their nephrologists a rating of 6 or less than 6 on a scale of 0 (worst possible) to 10 (best possible). | 6% | 14% |
News Archive
In a major step toward commercialization of a promising therapeutic treatment, Oak Ridge National Laboratory contractor UT-Battelle announced at a signing ceremony here today that it has exclusively licensed patents on inventions based on the Nell-1 gene to NellOne Therapeutics, Inc. (NellOne), a company spun out of research performed at the Department of Energy laboratory.
DaVita Clinical Research, a specialty contract research organization with services spanning a broad spectrum of drug and device development, announced today its Biospecimen Research Grant Program (BioReG), a grant program to award clinical-trial-quality biospecimens and annotated de-identified data to academic medical centers involved in kidney research.
Magellan Biosciences, a global manufacturer of products designed to make diagnostic testing easier, more cost-effective, and less labor intensive, announced that it has sold its microbiology business, TREK Diagnostic Systems, to Thermo Fisher Scientific.
NexBio, Inc. announced today the initiation of a trial of DAS181 (Fludase®) in patients with the respiratory conditions asthma and bronchiectasis, being conducted by researchers with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH). This trial will examine the effects of DAS181 in subjects with well-controlled or stable pulmonary disease.
Concentric Medical, Inc., the global leader in acute ischemic stroke intervention, today announced that its Trevo System for acute ischemic stroke has received regulatory approval in both Europe (CE Mark) and Canada.
› Verified 5 days ago
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Patients who reported that dialysis center staff always communicated well, kept patients comfortable and pain-free as possible. | 66% | 62% |
| Patients who reported that dialysis center staff usually communicated, kept patients comfortable and pain-free as possible. | 21% | 20% |
| Patients who reported that dialysis center staff sometimes or never communicated, kept patients comfortable and pain-free. | 13% | 18% |
| Patients who gave their dialysis facility staff a rating of 9 or 10 on a scale of 0 (worst possible) to 10 (best possible). | 74% | 62% |
| Patients who gave their dialysis facility staff a rating of 7 or 8 on a scale of 0 (worst possible) to 10 (best possible). | 22% | 26% |
| Patients who gave their dialysis facility staff a rating of 6 or less than 6 on a scale of 0 (worst possible) to 10 (best possible). | 4% | 12% |
News Archive
In a major step toward commercialization of a promising therapeutic treatment, Oak Ridge National Laboratory contractor UT-Battelle announced at a signing ceremony here today that it has exclusively licensed patents on inventions based on the Nell-1 gene to NellOne Therapeutics, Inc. (NellOne), a company spun out of research performed at the Department of Energy laboratory.
DaVita Clinical Research, a specialty contract research organization with services spanning a broad spectrum of drug and device development, announced today its Biospecimen Research Grant Program (BioReG), a grant program to award clinical-trial-quality biospecimens and annotated de-identified data to academic medical centers involved in kidney research.
Magellan Biosciences, a global manufacturer of products designed to make diagnostic testing easier, more cost-effective, and less labor intensive, announced that it has sold its microbiology business, TREK Diagnostic Systems, to Thermo Fisher Scientific.
NexBio, Inc. announced today the initiation of a trial of DAS181 (Fludase®) in patients with the respiratory conditions asthma and bronchiectasis, being conducted by researchers with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH). This trial will examine the effects of DAS181 in subjects with well-controlled or stable pulmonary disease.
Concentric Medical, Inc., the global leader in acute ischemic stroke intervention, today announced that its Trevo System for acute ischemic stroke has received regulatory approval in both Europe (CE Mark) and Canada.
› Verified 5 days ago
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Patients who reported that 'YES', their nephrologists and dialysis center staff provided them the information they needed to take care of them. | 87% | 80% |
| Patients who reported that 'NO', their nephrologists and dialysis center staff does not provided them the information they needed to take care of them. | 13% | 20% |
| Patients who gave their dialysis center a rating of 9 or 10 on a scale of 0 (worst possible) to 10 (best possible). | 66% | 68% |
| Patients who gave their dialysis center a rating of 7 or 8 on a scale of 0 (worst possible) to 10 (best possible). | 31% | 20% |
| Patients who gave their dialysis center a rating of 6 or less than 6 on a scale of 0 (worst possible) to 10 (best possible). | 3% | 12% |
News Archive
In a major step toward commercialization of a promising therapeutic treatment, Oak Ridge National Laboratory contractor UT-Battelle announced at a signing ceremony here today that it has exclusively licensed patents on inventions based on the Nell-1 gene to NellOne Therapeutics, Inc. (NellOne), a company spun out of research performed at the Department of Energy laboratory.
DaVita Clinical Research, a specialty contract research organization with services spanning a broad spectrum of drug and device development, announced today its Biospecimen Research Grant Program (BioReG), a grant program to award clinical-trial-quality biospecimens and annotated de-identified data to academic medical centers involved in kidney research.
Magellan Biosciences, a global manufacturer of products designed to make diagnostic testing easier, more cost-effective, and less labor intensive, announced that it has sold its microbiology business, TREK Diagnostic Systems, to Thermo Fisher Scientific.
NexBio, Inc. announced today the initiation of a trial of DAS181 (Fludase®) in patients with the respiratory conditions asthma and bronchiectasis, being conducted by researchers with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH). This trial will examine the effects of DAS181 in subjects with well-controlled or stable pulmonary disease.
Concentric Medical, Inc., the global leader in acute ischemic stroke intervention, today announced that its Trevo System for acute ischemic stroke has received regulatory approval in both Europe (CE Mark) and Canada.
› Verified 5 days ago
| Dialysis patients with Hemoglobin data | 47 |
| Medicare patients who had average hemoglobin (hgb) less than 10 g/dL | 17 |
News Archive
In a major step toward commercialization of a promising therapeutic treatment, Oak Ridge National Laboratory contractor UT-Battelle announced at a signing ceremony here today that it has exclusively licensed patents on inventions based on the Nell-1 gene to NellOne Therapeutics, Inc. (NellOne), a company spun out of research performed at the Department of Energy laboratory.
DaVita Clinical Research, a specialty contract research organization with services spanning a broad spectrum of drug and device development, announced today its Biospecimen Research Grant Program (BioReG), a grant program to award clinical-trial-quality biospecimens and annotated de-identified data to academic medical centers involved in kidney research.
Magellan Biosciences, a global manufacturer of products designed to make diagnostic testing easier, more cost-effective, and less labor intensive, announced that it has sold its microbiology business, TREK Diagnostic Systems, to Thermo Fisher Scientific.
NexBio, Inc. announced today the initiation of a trial of DAS181 (Fludase®) in patients with the respiratory conditions asthma and bronchiectasis, being conducted by researchers with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH). This trial will examine the effects of DAS181 in subjects with well-controlled or stable pulmonary disease.
Concentric Medical, Inc., the global leader in acute ischemic stroke intervention, today announced that its Trevo System for acute ischemic stroke has received regulatory approval in both Europe (CE Mark) and Canada.
› Verified 5 days ago
Adult patinets who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be atleast 1.7, that means they are receiving right amount of dialysis. Pediatric patients who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be 1.8.
Higher percentages should be better.
| Adult patients getting regular hemodialysis at the center | 98 |
| Adult patient months included in Kt/V greater than or equal to 1.2 | 807 |
| Percentage of adult patients getting regular hemodialysis at the center | 95 |
| Percentage of pediatric patients getting regular hemodialysis at the center |
News Archive
In a major step toward commercialization of a promising therapeutic treatment, Oak Ridge National Laboratory contractor UT-Battelle announced at a signing ceremony here today that it has exclusively licensed patents on inventions based on the Nell-1 gene to NellOne Therapeutics, Inc. (NellOne), a company spun out of research performed at the Department of Energy laboratory.
DaVita Clinical Research, a specialty contract research organization with services spanning a broad spectrum of drug and device development, announced today its Biospecimen Research Grant Program (BioReG), a grant program to award clinical-trial-quality biospecimens and annotated de-identified data to academic medical centers involved in kidney research.
Magellan Biosciences, a global manufacturer of products designed to make diagnostic testing easier, more cost-effective, and less labor intensive, announced that it has sold its microbiology business, TREK Diagnostic Systems, to Thermo Fisher Scientific.
NexBio, Inc. announced today the initiation of a trial of DAS181 (Fludase®) in patients with the respiratory conditions asthma and bronchiectasis, being conducted by researchers with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH). This trial will examine the effects of DAS181 in subjects with well-controlled or stable pulmonary disease.
Concentric Medical, Inc., the global leader in acute ischemic stroke intervention, today announced that its Trevo System for acute ischemic stroke has received regulatory approval in both Europe (CE Mark) and Canada.
› Verified 5 days ago
| Adult patients getting regular peritoneal dialysis at the center | 16 |
| Adult patient months included in Kt/V greater than or equal to 1.7 | 151 |
| Percentage of adult patients getting regular peritoneal dialysis at the center | 95 |
| Percentage of pediatric patients getting regular peritoneal dialysis at the center |
News Archive
In a major step toward commercialization of a promising therapeutic treatment, Oak Ridge National Laboratory contractor UT-Battelle announced at a signing ceremony here today that it has exclusively licensed patents on inventions based on the Nell-1 gene to NellOne Therapeutics, Inc. (NellOne), a company spun out of research performed at the Department of Energy laboratory.
DaVita Clinical Research, a specialty contract research organization with services spanning a broad spectrum of drug and device development, announced today its Biospecimen Research Grant Program (BioReG), a grant program to award clinical-trial-quality biospecimens and annotated de-identified data to academic medical centers involved in kidney research.
Magellan Biosciences, a global manufacturer of products designed to make diagnostic testing easier, more cost-effective, and less labor intensive, announced that it has sold its microbiology business, TREK Diagnostic Systems, to Thermo Fisher Scientific.
NexBio, Inc. announced today the initiation of a trial of DAS181 (Fludase®) in patients with the respiratory conditions asthma and bronchiectasis, being conducted by researchers with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH). This trial will examine the effects of DAS181 in subjects with well-controlled or stable pulmonary disease.
Concentric Medical, Inc., the global leader in acute ischemic stroke intervention, today announced that its Trevo System for acute ischemic stroke has received regulatory approval in both Europe (CE Mark) and Canada.
› Verified 5 days ago
An important goal of dialysis is to maintain normal levels of various minerals in the body, such as calcium. This shows the percentage of patients treated at Davita Battle Creek Dialysis with elevated calcium levels.
| Patients with hypercalcemia | 118 |
| Hypercalcemia patient months | 1026 |
| Patients with Serumphosphor | 123 |
| Patients with Serumphosphor less than 3.5 mg/dL | 14 |
| Patients with Serumphosphor from 3.5 to 4.5 mg/dL | 31 |
| Patients with Serumphosphor from 4.6 to 5.5 mg/dL | 32 |
| Patients with Serumphosphor from 5.6 to 7 mg/dL | 13 |
| Patients with Serumphosphor greater than 7 mg/dL | 9 |
News Archive
In a major step toward commercialization of a promising therapeutic treatment, Oak Ridge National Laboratory contractor UT-Battelle announced at a signing ceremony here today that it has exclusively licensed patents on inventions based on the Nell-1 gene to NellOne Therapeutics, Inc. (NellOne), a company spun out of research performed at the Department of Energy laboratory.
DaVita Clinical Research, a specialty contract research organization with services spanning a broad spectrum of drug and device development, announced today its Biospecimen Research Grant Program (BioReG), a grant program to award clinical-trial-quality biospecimens and annotated de-identified data to academic medical centers involved in kidney research.
Magellan Biosciences, a global manufacturer of products designed to make diagnostic testing easier, more cost-effective, and less labor intensive, announced that it has sold its microbiology business, TREK Diagnostic Systems, to Thermo Fisher Scientific.
NexBio, Inc. announced today the initiation of a trial of DAS181 (Fludase®) in patients with the respiratory conditions asthma and bronchiectasis, being conducted by researchers with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH). This trial will examine the effects of DAS181 in subjects with well-controlled or stable pulmonary disease.
Concentric Medical, Inc., the global leader in acute ischemic stroke intervention, today announced that its Trevo System for acute ischemic stroke has received regulatory approval in both Europe (CE Mark) and Canada.
› Verified 5 days ago
The arteriovenous (AV) fistulae is considered long term vascular access for hemodialysis because it allows good blood flow, lasts a long time, and is less likely to get infected or cause blood clots than other types of access. Patients who don't have time to get a permanent vascular access before they start hemodialysis treatments may need to use a venous catheter as a temporary access.
| Patients included in arterial venous fistula and catheter summaries | 69 |
| Patient months included in arterial venous fistula and catheter summaries | 505 |
| Percentage of patients getting regular hemodialysis at the center that used an arteriovenous (AV) fistulae for their treatment | 57 |
| Percentage of patients receiving treatment through Vascular Catheter for 90 days/longer | 3 |
News Archive
In a major step toward commercialization of a promising therapeutic treatment, Oak Ridge National Laboratory contractor UT-Battelle announced at a signing ceremony here today that it has exclusively licensed patents on inventions based on the Nell-1 gene to NellOne Therapeutics, Inc. (NellOne), a company spun out of research performed at the Department of Energy laboratory.
DaVita Clinical Research, a specialty contract research organization with services spanning a broad spectrum of drug and device development, announced today its Biospecimen Research Grant Program (BioReG), a grant program to award clinical-trial-quality biospecimens and annotated de-identified data to academic medical centers involved in kidney research.
Magellan Biosciences, a global manufacturer of products designed to make diagnostic testing easier, more cost-effective, and less labor intensive, announced that it has sold its microbiology business, TREK Diagnostic Systems, to Thermo Fisher Scientific.
NexBio, Inc. announced today the initiation of a trial of DAS181 (Fludase®) in patients with the respiratory conditions asthma and bronchiectasis, being conducted by researchers with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH). This trial will examine the effects of DAS181 in subjects with well-controlled or stable pulmonary disease.
Concentric Medical, Inc., the global leader in acute ischemic stroke intervention, today announced that its Trevo System for acute ischemic stroke has received regulatory approval in both Europe (CE Mark) and Canada.
› Verified 5 days ago
The rate of hospitalization show you whether patients who were being treated regularly at a certain dialysis center were admitted to the hospital more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other centers.
| Standard Hospitalization Summary Ratio(SHR) Year | January, 2016 - December, 2016 |
| Patients in facility's Hospitalization Summary | 90 |
| Hospitalization Rate in facility | 154.4 (As Expected) |
| Hospitalization Rate: Upper Confidence Limit | 248.4 |
| Hospitalization Rate: Lower Confidence Limit | 98.4 |
News Archive
In a major step toward commercialization of a promising therapeutic treatment, Oak Ridge National Laboratory contractor UT-Battelle announced at a signing ceremony here today that it has exclusively licensed patents on inventions based on the Nell-1 gene to NellOne Therapeutics, Inc. (NellOne), a company spun out of research performed at the Department of Energy laboratory.
DaVita Clinical Research, a specialty contract research organization with services spanning a broad spectrum of drug and device development, announced today its Biospecimen Research Grant Program (BioReG), a grant program to award clinical-trial-quality biospecimens and annotated de-identified data to academic medical centers involved in kidney research.
Magellan Biosciences, a global manufacturer of products designed to make diagnostic testing easier, more cost-effective, and less labor intensive, announced that it has sold its microbiology business, TREK Diagnostic Systems, to Thermo Fisher Scientific.
NexBio, Inc. announced today the initiation of a trial of DAS181 (Fludase®) in patients with the respiratory conditions asthma and bronchiectasis, being conducted by researchers with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH). This trial will examine the effects of DAS181 in subjects with well-controlled or stable pulmonary disease.
Concentric Medical, Inc., the global leader in acute ischemic stroke intervention, today announced that its Trevo System for acute ischemic stroke has received regulatory approval in both Europe (CE Mark) and Canada.
› Verified 5 days ago
The rate of readmission show you whether patients who were being treated regularly at Davita Battle Creek Dialysis were readmitted more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other dialysis centers.
| Standard Readmission Summary Ratio(SRR) Year | January, 2016 - December, 2016 |
| Readmission Rate in facility | 22.8 (As Expected) |
| Readmission Rate: Upper Confidence Limit | 30.8 |
| Readmission Rate: Lower Confidence Limit | 16 |
News Archive
In a major step toward commercialization of a promising therapeutic treatment, Oak Ridge National Laboratory contractor UT-Battelle announced at a signing ceremony here today that it has exclusively licensed patents on inventions based on the Nell-1 gene to NellOne Therapeutics, Inc. (NellOne), a company spun out of research performed at the Department of Energy laboratory.
DaVita Clinical Research, a specialty contract research organization with services spanning a broad spectrum of drug and device development, announced today its Biospecimen Research Grant Program (BioReG), a grant program to award clinical-trial-quality biospecimens and annotated de-identified data to academic medical centers involved in kidney research.
Magellan Biosciences, a global manufacturer of products designed to make diagnostic testing easier, more cost-effective, and less labor intensive, announced that it has sold its microbiology business, TREK Diagnostic Systems, to Thermo Fisher Scientific.
NexBio, Inc. announced today the initiation of a trial of DAS181 (Fludase®) in patients with the respiratory conditions asthma and bronchiectasis, being conducted by researchers with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH). This trial will examine the effects of DAS181 in subjects with well-controlled or stable pulmonary disease.
Concentric Medical, Inc., the global leader in acute ischemic stroke intervention, today announced that its Trevo System for acute ischemic stroke has received regulatory approval in both Europe (CE Mark) and Canada.
› Verified 5 days ago
Hemodialysis treatment requires direct access to the bloodstream, which can be an opportunity for germs to enter the body and cause infection. This information shows how often patients at Davita Battle Creek Dialysis get infections in their blood each year compared to the number of infections expected for the center based on the national average.
| Standard Infection Summary Ratio(SIR) Year | January, 2016 - December, 2016 |
| Infection Rate in facility | 1.45 (As Expected) |
| SIR: Upper Confidence Limit | 2.87 |
| SIR: Lower Confidence Limit | .63 |
News Archive
In a major step toward commercialization of a promising therapeutic treatment, Oak Ridge National Laboratory contractor UT-Battelle announced at a signing ceremony here today that it has exclusively licensed patents on inventions based on the Nell-1 gene to NellOne Therapeutics, Inc. (NellOne), a company spun out of research performed at the Department of Energy laboratory.
DaVita Clinical Research, a specialty contract research organization with services spanning a broad spectrum of drug and device development, announced today its Biospecimen Research Grant Program (BioReG), a grant program to award clinical-trial-quality biospecimens and annotated de-identified data to academic medical centers involved in kidney research.
Magellan Biosciences, a global manufacturer of products designed to make diagnostic testing easier, more cost-effective, and less labor intensive, announced that it has sold its microbiology business, TREK Diagnostic Systems, to Thermo Fisher Scientific.
NexBio, Inc. announced today the initiation of a trial of DAS181 (Fludase®) in patients with the respiratory conditions asthma and bronchiectasis, being conducted by researchers with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH). This trial will examine the effects of DAS181 in subjects with well-controlled or stable pulmonary disease.
Concentric Medical, Inc., the global leader in acute ischemic stroke intervention, today announced that its Trevo System for acute ischemic stroke has received regulatory approval in both Europe (CE Mark) and Canada.
› Verified 5 days ago
Patients with anemia require blood transfusions if their anemia is not managed well by their dialysis center. This information shows whether Davita Battle Creek Dialysis's rate of transfusions is better than expected, as expected, or worse than expected, compared to other centers that treat similar patients.
| Standard Transfusion Summary Ratio (STrR) Year | January, 2016 - December, 2016 |
| Patients in facility's Transfusion Summary | 77 |
| Transfusion Rate in facility | 32 (As Expected) |
| Transfusion Rate: Upper Confidence Limit | 73.5 |
| Transfusion Rate: Lower Confidence Limit | 15.4 |
News Archive
In a major step toward commercialization of a promising therapeutic treatment, Oak Ridge National Laboratory contractor UT-Battelle announced at a signing ceremony here today that it has exclusively licensed patents on inventions based on the Nell-1 gene to NellOne Therapeutics, Inc. (NellOne), a company spun out of research performed at the Department of Energy laboratory.
DaVita Clinical Research, a specialty contract research organization with services spanning a broad spectrum of drug and device development, announced today its Biospecimen Research Grant Program (BioReG), a grant program to award clinical-trial-quality biospecimens and annotated de-identified data to academic medical centers involved in kidney research.
Magellan Biosciences, a global manufacturer of products designed to make diagnostic testing easier, more cost-effective, and less labor intensive, announced that it has sold its microbiology business, TREK Diagnostic Systems, to Thermo Fisher Scientific.
NexBio, Inc. announced today the initiation of a trial of DAS181 (Fludase®) in patients with the respiratory conditions asthma and bronchiectasis, being conducted by researchers with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH). This trial will examine the effects of DAS181 in subjects with well-controlled or stable pulmonary disease.
Concentric Medical, Inc., the global leader in acute ischemic stroke intervention, today announced that its Trevo System for acute ischemic stroke has received regulatory approval in both Europe (CE Mark) and Canada.
› Verified 5 days ago
The rate of mortality show you whether patients who were being treated regularly at Davita Battle Creek Dialysis lived longer than expected (better than expected), don’t live as long as expected (worse than expected), or lived as long as expected (as expected), compared to similar patients treated at other facilities.
| Standard Survival Summary Ratio(SIR) Year | January, 2013 - December, 2016 |
| Patients in facility's Survival Summary | 480 |
| Mortality Rate in facility | 12.8 (Better than Expected) |
| Mortality Rate: Upper Confidence Limit | 16.1 |
| Mortality Rate: Lower Confidence Limit | 10 |
News Archive
In a major step toward commercialization of a promising therapeutic treatment, Oak Ridge National Laboratory contractor UT-Battelle announced at a signing ceremony here today that it has exclusively licensed patents on inventions based on the Nell-1 gene to NellOne Therapeutics, Inc. (NellOne), a company spun out of research performed at the Department of Energy laboratory.
DaVita Clinical Research, a specialty contract research organization with services spanning a broad spectrum of drug and device development, announced today its Biospecimen Research Grant Program (BioReG), a grant program to award clinical-trial-quality biospecimens and annotated de-identified data to academic medical centers involved in kidney research.
Magellan Biosciences, a global manufacturer of products designed to make diagnostic testing easier, more cost-effective, and less labor intensive, announced that it has sold its microbiology business, TREK Diagnostic Systems, to Thermo Fisher Scientific.
NexBio, Inc. announced today the initiation of a trial of DAS181 (Fludase®) in patients with the respiratory conditions asthma and bronchiectasis, being conducted by researchers with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH). This trial will examine the effects of DAS181 in subjects with well-controlled or stable pulmonary disease.
Concentric Medical, Inc., the global leader in acute ischemic stroke intervention, today announced that its Trevo System for acute ischemic stroke has received regulatory approval in both Europe (CE Mark) and Canada.
› Verified 5 days ago
FMC - Battle Creek South Location: 2845 Capital Ave Sw, Ste 102, Battle Creek, Michigan, 49015 Phone: (269) 979-8865 |
Davita Battle Creek Dialysis Location: 220 Goodale Ave E Ste B, Battle Creek, Michigan, 49037 Phone: (269) 968-8401 |
FMC - Battle Creek North Location: 233 E Roosevelt Ave, Battle Creek, Michigan, 49017 Phone: (269) 968-8860 |
News Archive
In a major step toward commercialization of a promising therapeutic treatment, Oak Ridge National Laboratory contractor UT-Battelle announced at a signing ceremony here today that it has exclusively licensed patents on inventions based on the Nell-1 gene to NellOne Therapeutics, Inc. (NellOne), a company spun out of research performed at the Department of Energy laboratory.
DaVita Clinical Research, a specialty contract research organization with services spanning a broad spectrum of drug and device development, announced today its Biospecimen Research Grant Program (BioReG), a grant program to award clinical-trial-quality biospecimens and annotated de-identified data to academic medical centers involved in kidney research.
Magellan Biosciences, a global manufacturer of products designed to make diagnostic testing easier, more cost-effective, and less labor intensive, announced that it has sold its microbiology business, TREK Diagnostic Systems, to Thermo Fisher Scientific.
NexBio, Inc. announced today the initiation of a trial of DAS181 (Fludase®) in patients with the respiratory conditions asthma and bronchiectasis, being conducted by researchers with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH). This trial will examine the effects of DAS181 in subjects with well-controlled or stable pulmonary disease.
Concentric Medical, Inc., the global leader in acute ischemic stroke intervention, today announced that its Trevo System for acute ischemic stroke has received regulatory approval in both Europe (CE Mark) and Canada.
› Verified 5 days ago